Cargando…
The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial
INTRODUCTION: COVID-19 is severely affecting countries globally and mortality is high. Xuebijing (XBJ) injection is widely used in the treatment of severe pneumonia and sepsis in China due to its anti-inflammatory effect and immunoregulation. This study investigated whether Xuebijing injection can p...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier GmbH.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847185/ https://www.ncbi.nlm.nih.gov/pubmed/33552315 http://dx.doi.org/10.1016/j.eujim.2021.101305 |
_version_ | 1783644881006100480 |
---|---|
author | Luo, Zhijian Chen, Wei Xiang, Mingqing Wang, Hua Xiao, Wei Xu, Cheng Li, Yunkui Min, Jie Tu, Qiang |
author_facet | Luo, Zhijian Chen, Wei Xiang, Mingqing Wang, Hua Xiao, Wei Xu, Cheng Li, Yunkui Min, Jie Tu, Qiang |
author_sort | Luo, Zhijian |
collection | PubMed |
description | INTRODUCTION: COVID-19 is severely affecting countries globally and mortality is high. Xuebijing (XBJ) injection is widely used in the treatment of severe pneumonia and sepsis in China due to its anti-inflammatory effect and immunoregulation. This study investigated whether Xuebijing injection can prevent the cytokine storm and reduce the mortality from severe COVID-19. METHODS: This was a randomized, double-blinded trial in which 60 eligible patients were recruited from the First people's Hospital of Jingzhou from February 16 to March 25 in 2020. A total of 57 completed the trial, 3 dropped out. The treatment group received routine medication plus Xuebijing injection while the control group received routine medication plus saline. RESULTS: The secretion of interleukin-6(IL-6), interleukin-8(IL-8) and tumor necrosis factor-α(TNF-α) was suppressed significantly (P < 0.05) by Xuebijing. After 14 days treatment, lymphocyte levels in Xuebijing group was substantially higher than control, C-reactive protein (CRP) level in Xuebijing group was remarkably lower. The 28-day mortality was not significantly different between the two group. After 14 days of treatment, there were significant differences in the rate of mechanical ventilation, rate of septic shock, the proportion of patients severely affected who became critically ill, the duration of improvement of main clinical symptoms (P < 0.05) and the length of ICU hospitalization stay (P < 0.01) for the Xuebijing group compared with controls. No serious adverse reactions were identified in either group. CONCLUSIONS: This study demonstrates that Xuebijing injection may suppress the cytokine storm in severe COVID-19 patients by regulating the secretion of pro- inflammatory cytokine IL-6, IL-8 and TNF -α. However, Xuebijing did not significantly reduce the 28-day mortality. |
format | Online Article Text |
id | pubmed-7847185 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier GmbH. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78471852021-02-01 The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial Luo, Zhijian Chen, Wei Xiang, Mingqing Wang, Hua Xiao, Wei Xu, Cheng Li, Yunkui Min, Jie Tu, Qiang Eur J Integr Med Clinical Trial INTRODUCTION: COVID-19 is severely affecting countries globally and mortality is high. Xuebijing (XBJ) injection is widely used in the treatment of severe pneumonia and sepsis in China due to its anti-inflammatory effect and immunoregulation. This study investigated whether Xuebijing injection can prevent the cytokine storm and reduce the mortality from severe COVID-19. METHODS: This was a randomized, double-blinded trial in which 60 eligible patients were recruited from the First people's Hospital of Jingzhou from February 16 to March 25 in 2020. A total of 57 completed the trial, 3 dropped out. The treatment group received routine medication plus Xuebijing injection while the control group received routine medication plus saline. RESULTS: The secretion of interleukin-6(IL-6), interleukin-8(IL-8) and tumor necrosis factor-α(TNF-α) was suppressed significantly (P < 0.05) by Xuebijing. After 14 days treatment, lymphocyte levels in Xuebijing group was substantially higher than control, C-reactive protein (CRP) level in Xuebijing group was remarkably lower. The 28-day mortality was not significantly different between the two group. After 14 days of treatment, there were significant differences in the rate of mechanical ventilation, rate of septic shock, the proportion of patients severely affected who became critically ill, the duration of improvement of main clinical symptoms (P < 0.05) and the length of ICU hospitalization stay (P < 0.01) for the Xuebijing group compared with controls. No serious adverse reactions were identified in either group. CONCLUSIONS: This study demonstrates that Xuebijing injection may suppress the cytokine storm in severe COVID-19 patients by regulating the secretion of pro- inflammatory cytokine IL-6, IL-8 and TNF -α. However, Xuebijing did not significantly reduce the 28-day mortality. Elsevier GmbH. 2021-02 2021-01-30 /pmc/articles/PMC7847185/ /pubmed/33552315 http://dx.doi.org/10.1016/j.eujim.2021.101305 Text en © 2021 Elsevier GmbH. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Clinical Trial Luo, Zhijian Chen, Wei Xiang, Mingqing Wang, Hua Xiao, Wei Xu, Cheng Li, Yunkui Min, Jie Tu, Qiang The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial |
title | The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial |
title_full | The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial |
title_fullStr | The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial |
title_full_unstemmed | The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial |
title_short | The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial |
title_sort | preventive effect of xuebijing injection against cytokine storm for severe patients with covid-19: a prospective randomized controlled trial |
topic | Clinical Trial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847185/ https://www.ncbi.nlm.nih.gov/pubmed/33552315 http://dx.doi.org/10.1016/j.eujim.2021.101305 |
work_keys_str_mv | AT luozhijian thepreventiveeffectofxuebijinginjectionagainstcytokinestormforseverepatientswithcovid19aprospectiverandomizedcontrolledtrial AT chenwei thepreventiveeffectofxuebijinginjectionagainstcytokinestormforseverepatientswithcovid19aprospectiverandomizedcontrolledtrial AT xiangmingqing thepreventiveeffectofxuebijinginjectionagainstcytokinestormforseverepatientswithcovid19aprospectiverandomizedcontrolledtrial AT wanghua thepreventiveeffectofxuebijinginjectionagainstcytokinestormforseverepatientswithcovid19aprospectiverandomizedcontrolledtrial AT xiaowei thepreventiveeffectofxuebijinginjectionagainstcytokinestormforseverepatientswithcovid19aprospectiverandomizedcontrolledtrial AT xucheng thepreventiveeffectofxuebijinginjectionagainstcytokinestormforseverepatientswithcovid19aprospectiverandomizedcontrolledtrial AT liyunkui thepreventiveeffectofxuebijinginjectionagainstcytokinestormforseverepatientswithcovid19aprospectiverandomizedcontrolledtrial AT minjie thepreventiveeffectofxuebijinginjectionagainstcytokinestormforseverepatientswithcovid19aprospectiverandomizedcontrolledtrial AT tuqiang thepreventiveeffectofxuebijinginjectionagainstcytokinestormforseverepatientswithcovid19aprospectiverandomizedcontrolledtrial AT luozhijian preventiveeffectofxuebijinginjectionagainstcytokinestormforseverepatientswithcovid19aprospectiverandomizedcontrolledtrial AT chenwei preventiveeffectofxuebijinginjectionagainstcytokinestormforseverepatientswithcovid19aprospectiverandomizedcontrolledtrial AT xiangmingqing preventiveeffectofxuebijinginjectionagainstcytokinestormforseverepatientswithcovid19aprospectiverandomizedcontrolledtrial AT wanghua preventiveeffectofxuebijinginjectionagainstcytokinestormforseverepatientswithcovid19aprospectiverandomizedcontrolledtrial AT xiaowei preventiveeffectofxuebijinginjectionagainstcytokinestormforseverepatientswithcovid19aprospectiverandomizedcontrolledtrial AT xucheng preventiveeffectofxuebijinginjectionagainstcytokinestormforseverepatientswithcovid19aprospectiverandomizedcontrolledtrial AT liyunkui preventiveeffectofxuebijinginjectionagainstcytokinestormforseverepatientswithcovid19aprospectiverandomizedcontrolledtrial AT minjie preventiveeffectofxuebijinginjectionagainstcytokinestormforseverepatientswithcovid19aprospectiverandomizedcontrolledtrial AT tuqiang preventiveeffectofxuebijinginjectionagainstcytokinestormforseverepatientswithcovid19aprospectiverandomizedcontrolledtrial |